

AMERICAN SOFTWARE INC
 Form 4
 May 01, 2008

FORM 4

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION
 Washington, D.C. 20549**

OMB APPROVAL

OMB Number: 3235-0287
 Expires: January 31, 2005
 Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person *
 NEWBERRY THOMAS L

2. Issuer Name and Ticker or Trading Symbol
 AMERICAN SOFTWARE INC
 [AMSWA]

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

(Last) (First) (Middle)
 470 EAST PACES FERRY ROAD
 (Street)

3. Date of Earliest Transaction (Month/Day/Year)
 04/30/2008

Director 10% Owner
 Officer (give title below) Other (specify below)

ATLANTA, GA 30305
 (City) (State) (Zip)

4. If Amendment, Date Original Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check Applicable Line)
 Form filed by One Reporting Person
 Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Ownership (Instr. 4)
				(A) or (D)	Price		
				Code	V	Amount	Price
Class A Common Stock						41,225	D
Class B Stock						904,999	D

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474
 (9-02)

Edgar Filing: AMERICAN SOFTWARE INC - Form 4

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)	7. Title and Amount of Underlying Securities (Instr. 3 and 4)	8. Amount or Number of Shares
Options to Acquire Class A Common Stock	\$ 6.16	04/30/2008		A	3,000	04/30/2009 04/30/2014	Class A Common Stock	3,000

Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
NEWBERRY THOMAS L 470 EAST PACES FERRY ROAD ATLANTA, GA 30305		X		

Signatures

Thomas L. Newberry 05/01/2008

**Signature of Reporting Person Date

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number. left: Black 1pt solid; text-align: left; vertical-align: bottom">**The biopharmaceuticals segment** Haemophilia2,8361,2481,2081,58863351956151229Norditropin® (human growth hormone) 2,4071,4211,420986404197432952Other biopharmaceuticals938699649239159551222Biopharmaceuticals total6,1813,3683,2772,8131,19677161502283Total sales27,21214,19713,73013,0155,0163,0112,8751,335778 Q2 2016 sales split per region - DKK millionTotalNorth

AmericaHereof
USAInternational
operationsEuropeAfrica, Asia,

Middle East &

OceaniaRegion ChinaJapan &

KoreaLatin AmericaThe diabetes and obesity care segment New generation

insulin**983**46146152220463-19164Modern insulin**11,806**6,4466,2655,3602,2531,2591,202466180**NovoRapid**

®**4,890**2,7832,6912,1071,06446026225665**NovoMix** ®**2,651**5495362,10252657281216428**Levemir**

®**4,265**3,1143,0381,1516632271284687Human

insulin**2,667**4083602,25950865581080206**Victoza**®**4,952**3,5723,4501,3808921786016090Other diabetes and obesity

care**1,391**57752181416213439111215**Saxenda** ®**376**3583391868--4**Diabetes and obesity care**

total21,79911,46411,05710,3354,0192,2892,4631,009555The biopharmaceuticals

segment Haemophilia**2,530**1,2561,2141,27465424341194142**Norditropin**® (human growth

hormone)**2,158**1,0341,0341,124435254438249Other

biopharmaceuticals**972**69964227319056126-**Biopharmaceuticals**

total5,6602,9892,8902,6711,27955346602191Total sales27,45914,45313,94713,0065,2982,8422,5091,611746 Q3

2016 sales split per region - DKK million**TotalNorth**

AmericaHereof

USAInternational

operationsEuropeAfrica, Asia,

Middle East &

OceaniaRegion ChinaJapan &

KoreaLatin AmericaThe diabetes and obesity care segment New generation insulin**1,143**582

582

561

226

64

-

200

71

Modern insulin**11,770**6,375 6,1895,395 2,214 1,3271,229 457 168**NovoRapid** ®**4,888**2,736 2,6392,152 1,068 501263

256 64**NovoMix** ®**2,537**431 4182,106 495 607821 158 25**Levemir** ®**4,345**3,208 3,1321,137 651 219145 43 79Human

insulin**2,760**571 5262,189 489 626774 76 224**Victoza**®**5,106**3,770 3,6491,336 810 17170 166 119Other diabetes and

obesity care**1,513**643 580870 181 142430 90 27**Saxenda** ®**418**380 35538 7 15- - 16**Diabetes and obesity care**

total22,29211,941 11,52610,351 3,920 2,3302,503 989 609The biopharmaceuticals segment

Haemophilia **2,285** 1,212 1,135 1,073 593 131 27 177 145 Norditropin® (human growth hormone) **2,003** 892 892 1,111
 398 265 338 956 Other biopharmaceuticals **957** 674 621 283 182 641 33 3 **Biopharmaceuticals total** **5,245,778**
2,648,246 1,173 460 31 599 204 **Total sales** **27,537,147,191** 14,174 12,818 5,093 2,790 2,534 1,588 813 Q4 2016 sales split
 per region - DKK million **Total North**
America Hereof
USA International
operations Europe Africa, Asia,
Middle East &
Oceania Region China Japan &
Korea Latin America The diabetes and obesity care segment New generation insulin **1,707** 1,003 1,003 704

287

93

-

235

89

Modern insulin **12,219** 6,787 6,617 5,432 2,104 1,424 1,250 465 189 *NovoRapid* ® **5,539** 3,286 3,196 2,253 1,081 556 270
 269 77 *NovoMix* ® **2,596** 5,255 152,071 501 547 843 155 25 *Levemir* ® **4,084** 2,976 2,906 1,108 522 321 137 41 87 Human
 insulin **2,938** 602 557 2,336 605 609 830 78 214 *Victoza* ® **5,397** 3,983 3,862 1,414 857 186 60 171 140 Other diabetes and
 obesity care **1,566** 691 623 875 173 152 362 135 53 *Saxenda* ® **540** 475 448 65 12 18 - - 35 **Diabetes and obesity care**
total **23,827** 13,066 12,662 10,761 4,026 2,464 2,502 1,084 685 **The biopharmaceuticals segment**

Haemophilia **2,821** 1,218 1,153 1,603 640 208 34 215 506 Norditropin® (human growth hormone) **2,202** 1,151 1,149 1,051
 424 190 436 956 Other biopharmaceuticals **722** 438 379 284 185 75- 23 1 **Biopharmaceuticals**
total **5,745,807** 2,681 2,938 1,249 473 38 607 571 **Total**
sales **29,572** 15,873 15,343 13,699 5,275 2,937 2,540 1,691 1,256 Total 2016 sales split per region - DKK
 million **Total North**

America Hereof
USA International
operations Europe Africa, Asia,
Middle East &
Oceania Region China Japan &

Explanation of Responses:

Korea **Latin America** **The diabetes and obesity care segment** New generation
 insulin **4,459** 2,246 2,246 2,213 886 279-769 279 Modern
 insulin **47,510** 26,043 25,337 21,467 8,728 5,284 4,969 1,787 699 *NovoRapid*
 ® **19,945** 11,427 11,058 8,518 4,200 1,995 1,059 998 266 *NovoMix*
 ® **10,482** 2,080 2,032 8,402 2,025 2,291 3,363 619 104 *Levemir* ® **17,083** 12,536 12,247 4,547 2,503 998 547 170 329 Human
 insulin **11,090** 2,011 1,827 9,079 2,103 2,494 3,361 302 819 *Victoza* ® **20,046** 14,624 14,146 5,422 3,391 715 255 623 438 Other
 diabetes and obesity care **5,844** 2,376 2,142 3,468 677 511,697 434 109 *Saxenda* ® **1,577** 1,446 1,366 131 284 6--57 **Diabetes
 and obesity care total** **88,949** **47,300** **45,698** **41,649** **15,785** **9,323** **10,282** **3,915** **2,344** **The biopharmaceuticals segment**

Haemophilia **10,472** 4,934 4,710 5,538 2,520 1,101 158 737 1,022 *Norditropin*® (human growth
 hormone) **8,770** 4,498 4,495 4,272 1,661 906 151,469 221 Other
 biopharmaceuticals **3,589** 2,510 2,291 1,079 716 250 310 46 **Biopharmaceuticals
 total** **22,831** **11,942** **11,496** **10,889** **4,897** **2,257** **176** **2,310** **1,249** **Total
 sales** **111,780** **59,242** **57,194** **52,538** **20,682** **11,580** **10,458** **6,225** **3,593** **% change in local
 currencies** **6%** **4%** **4%** **7%** **2%** **7%** **12%** **4%** **28%** **% change as reported** **4%** **4%** **4%** **3%** **(1%)** **3%** **6%** **15%** **(3%)** **Share of
 growth** **100%** **41%** **37%** **59%** **5%** **14%** **19%** **4%** **17%**

Financial Performance Outlook R&D Sustainability Equity Corporate Governance Legal **Financial Information**

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf of the undersigned, thereunto duly authorized.

NOVO NORDISK A/S

Date: February 2, 2017

Lars Rebien Sørensen,

Chief Executive Officer